Risk factor
Very poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of AFME.PA is 3.5 and suggests 24% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell